Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Market Cap | 75.595 Million | Shares Outstanding | 99.729 Million | Avg 30-day Volume | 652.468 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.4 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -149.796 Million |
Price to Book Value | 0.4536 | Operating Margin | 0.0 | Enterprise Value | -108.763 Million |
Current Ratio | 7.451 | EPS Growth | -0.026 | Quick Ratio | 7.102 |
1 Yr BETA | 0.6055 | 52-week High/Low | 1.82 / 0.53 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -10.7358 | Altman Z-Score | -3.6696 | Free Cash Flow to Firm | -102.108 Million |
Please sign in first
none
61.9 Thousand total shares from 3 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
FISCHER LAURENT CEO, PRESIDENT AND DIRECTOR |
|
692,141 | 2023-03-15 | 5 |
SOPARKAR PETER CHIEF OPERATING OFFICER |
|
265,891 | 2023-03-15 | 5 |
RILEY BRIGIT CHIEF SCIENTIFIC OFFICER |
|
117,435 | 2023-03-15 | 4 |
SEYEDKAZEMI SETAREH CHIEF DEVELOPMENT OFFICER |
|
0 | 2023-03-01 | 4 |
BECKMAN RICHARD CHIEF MEDICAL OFFICER |
|
0 | 2023-03-01 | 5 |
RUBINSTEIN LINDA M CHIEF FINANCIAL OFFICER |
|
0 | 2022-12-12 | 1 |
RAKOW JOHN SVP, GENL COUNSEL, ACTING CFO |
|
118,070 | 2022-09-14 | 3 |
|
40,000 | 2022-06-10 | 1 | |
|
52,500 | 2022-06-10 | 1 | |
|
40,000 | 2022-06-10 | 1 | |
|
40,000 | 2022-06-10 | 1 | |
|
40,000 | 2022-06-10 | 2 | |
|
40,000 | 2022-06-10 | 1 | |
PECOTA NANCY E PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2022-06-06 | 1 |
D'SOUZA RUPERT CHIEF FINANCIAL OFFICER |
|
20,850 | 2022-05-13 | 1 |
|
0 | 2022-03-17 | 0 | |
|
80,000 | 2022-03-17 | 0 | |
CLARK JULIE CHIEF MEDICAL OFFICER |
|
164,723 | 2021-09-30 | 0 |
THRIFT JACK ANTHONY INTERIM CFO |
|
0 | 2021-09-02 | 0 |
THEDINGA ANGELA CHIEF TECHNOLOGY OFFICER |
|
270,000 | 2021-08-06 | 0 |
DERESPINO CHRISTOPHER SEE REMARKS |
|
0 | 2021-06-24 | 0 |
|
40,000 | 2021-05-12 | 0 | |
|
40,000 | 2021-05-12 | 0 | |
PATTERSON LEONE D PRESIDENT AND CFO |
|
0 | 2021-02-16 | 0 |
OSBORNE AARON CHIEF MEDICAL OFFICER |
|
0 | 2021-02-16 | 0 |
|
0 | 2020-06-23 | 0 | |
|
0 | 2020-06-23 | 0 | |
LEUNG THOMAS CHIEF FINANCIAL OFFICER |
|
0 | 2020-02-20 | 0 |
|
No longer subject to file | 2019-07-31 | 0 | |
|
0 | 2019-07-31 | 0 | |
CHENG JENNIFER C. GENERAL COUNSEL |
|
0 | 2019-02-14 | 0 |
|
0 | 2018-05-31 | 0 | |
COUNTOURIOTIS ATHENA SVP, CHIEF MEDICAL OFFICER |
|
0 | 2018-02-15 | 0 |
SALZMAN AMBER PRESIDENT AND CEO |
|
0 | 2018-02-15 | 0 |
|
398,991 | 2017-06-12 | 0 | |
BARONE SAMUEL B. SVP, CLINICAL DEVELOPMENT |
|
172,335 | 2017-02-09 | 0 |
|
7,003,892 | 2016-05-11 | 0 | |
RUSSO CARLO EVP AND CHIEF MEDICAL OFFICER |
|
0 | 2016-05-11 | 0 |
|
69,112 | 2016-02-29 | 0 | |
|
36,893 | 2016-02-12 | 0 | |
|
562,915 | 2016-02-12 | 0 | |
RUBIO ROMAN G. SVP, TRANSLATIONAL MEDICINE |
|
165,650 | 2016-02-12 | 0 |
BRAUN SHIRLEY VP, HUMAN RESOURCES |
|
161,140 | 2016-02-12 | 0 |
SWARTZBURG MICHAEL PRINCIPAL ACCOUNTING OFFICER |
|
82,113 | 2016-02-12 | 0 |
BAIN LINDA CHIEF FINANCIAL OFFICER |
|
41,930 | 2015-08-21 | 0 |
HULL HANS CHIEF EXECUTIVE OFFICER |
|
137,210 | 2015-08-21 | 0 |
CHALBERG THOMAS W. CHIEF EXECUTIVE OFFICER |
|
1,099,401 | 2015-06-10 | 0 |
|
200,000 | 2015-05-27 | 0 | |
|
No longer subject to file | 2015-04-13 | 0 | |
|
No longer subject to file | 2014-08-05 | 0 | |
DEERFIELD SPECIAL SITUATIONS FUND, L.P. DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. |
|
No longer subject to file | 2014-08-05 | 0 |
VENROCK PARTNERS MANAGEMENT VI, LLC VENROCK HEALTHCARE CAPITAL PARTNERS LP |
|
4,330,942 | 2014-08-05 | 0 |
VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P. |
|
4,330,942 | 2014-08-05 | 0 |
DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. |
|
0 | 2014-07-30 | 0 |
VENROCK PARTNERS MANAGEMENT VI, LLC VENROCK HEALTHCARE CAPITAL PARTNERS LP |
|
0 | 2014-07-30 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FISCHER LAURENT - Director - Officer CEO, PRESIDENT AND DIRECTOR |
2023-03-17 18:01:25 -0400 | 2023-03-15 | S | 41,239 | $0.78 | d | 692,141 | direct | -0.5089 | 0.0 | 1 | -0.5089 | 2 | |||
2023-03-17 18:02:59 -0400 | 2023-03-15 | S | 7,299 | $0.78 | d | 117,435 | direct | -0.5089 | 0.0 | 1 | -0.5089 | 2 | ||||
2023-03-17 18:02:15 -0400 | 2023-03-15 | S | 13,360 | $0.78 | d | 265,891 | direct | -0.5089 | 0.0 | 1 | -0.5089 | 2 | ||||
2023-03-03 17:24:02 -0500 | 2023-03-01 | A | 250,000 | a | 250,000 | direct | ||||||||||
2023-03-03 17:23:14 -0500 | 2023-03-01 | A | 225,000 | a | 225,000 | direct | ||||||||||
2023-03-03 17:24:23 -0500 | 2023-03-01 | A | 250,000 | a | 250,000 | direct | ||||||||||
FISCHER LAURENT - Director - Officer CEO, PRESIDENT AND DIRECTOR |
2023-03-03 17:21:33 -0500 | 2023-03-01 | A | 930,000 | a | 930,000 | direct | |||||||||
2023-03-03 17:22:20 -0500 | 2023-03-01 | A | 400,000 | a | 400,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 22:15:03 UTC | 3.0059 | 1.8141 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 21:45:03 UTC | 2.9655 | 1.8545 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 21:15:03 UTC | 2.9655 | 1.8545 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 20:45:03 UTC | 2.9657 | 1.8543 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 20:15:04 UTC | 2.9657 | 1.8543 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 19:45:03 UTC | 2.9657 | 1.8543 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 19:15:04 UTC | 2.9657 | 1.8543 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 18:45:04 UTC | 2.9736 | 1.8464 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 18:15:03 UTC | 2.9736 | 1.8464 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 17:45:03 UTC | 2.9736 | 1.8464 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 17:15:03 UTC | 2.9736 | 1.8464 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 16:45:03 UTC | 2.975 | 1.845 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 16:15:03 UTC | 2.975 | 1.845 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 15:45:03 UTC | 2.975 | 1.845 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 15:15:03 UTC | 2.975 | 1.845 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 14:45:03 UTC | 2.975 | 1.845 | 500000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 14:15:03 UTC | 2.975 | 1.845 | 700000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 13:45:03 UTC | 2.7458 | 1.8242 | 700000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 13:15:04 UTC | 2.7458 | 1.8242 | 700000 |
ADVERUM BIOTECHNOLOGIES INC ADVM | 2023-03-24 12:45:03 UTC | 2.7458 | 1.8242 | 700000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Trust for Professional Managers- Convergence Market Neutral Fund | ADVM | -5066.0 shares, $-61805.2 | 2020-08-31 | N-PORT |